Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03154333 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)
A Phase 2 study, sponsored by Castle Creek Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT03154333 is a Phase 2 study that was terminated before completion, run by Castle Creek Pharmaceuticals. The registered enrollment target is 54 participants.
The verdict
NCT03154333, a Phase 2 study, was terminated before completion, sponsored by Castle Creek Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
Epidermolysis bullosa simplex (EBS) is a rare genetic skin disease characterized by fragility of the skin and mucous membranes resulting in painful blisters and erosions after minor trauma. The purpose of this study is to compare the efficacy of diacerein 1% ointment to vehicle ointment when applied once-daily for 8 weeks in subjects with EBS.
Interventions
- DRUG diacerein 1% ointment
- DRUG A placebo ointment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2017-06-01 |
| Est. Completion | 2018-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03154333
The ClinicalTrials.gov registry entry for NCT03154333 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Castle Creek Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which diacerein 1% ointment is the first listed.
NCT03154333 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03154333 about?
NCT03154333 is a clinical study titled "Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)". Epidermolysis bullosa simplex (EBS) is a rare genetic skin disease characterized by fragility of the skin and mucous membranes resulting in painful blisters and erosions after minor trauma. The purpose of this study is to compare the efficacy of diacerein 1% ointment to vehicle ointment when applied...
What is the current status of trial NCT03154333?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2017-06-01. Estimated completion is 2018-10-31.
What interventions are being tested in trial NCT03154333?
The interventions under investigation include: diacerein 1% ointment (DRUG), A placebo ointment (DRUG).
Who is sponsoring clinical trial NCT03154333?
This trial is sponsored by Castle Creek Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.